News Update

PPMD Awards UCLA $50,000 Exploratory Grant for Evaluation of Exon Skipping Enhancers in Duchenne

PPMD is excited to award Dr. Carrie Miceli and her team at UCLA’s David Geffen School of Medicine and College of Letters and Science, a $50,000 exploratory grant to continue their evaluation of exon skipping boosters for the treatment of Duchenne.
January 29, 2014 | Learn more 

Join us in Washington, DC!

Get Active in Advocacy

2014 was a historic year in our community. 2015 promises to be another critical year in Duchenne and we need you to help keep the momentum going! With such a big year, it is more important than ever to get involved. Our Annual Advocacy Conference is one month away. We urge everyone to lend your voice, your story, to our efforts in Washington. You don’t have to travel to Washington to be an effective advocate.
January 28, 2014 | Learn more 


FDA Acknowledges the Importance of Benefit-Risk Preferences: Why this Matters to Duchenne

Recently the FDA approved a device used to treat obesity, based in part on the results of the preferences study that showed that patients would accept uncertainty about benefits. An FDA spokeswoman said that the FDA believes patients and caregivers who live with a condition should have a say when approving a product, and may have a different view about striking the right risk-benefit balance. This could have incredible significance in the Duchenne community and makes our ongoing benefit/risk work all the more critical.
January 26, 2014 | Learn more 

News Update

Important Vaccinations Recommendations

Vaccinations are important to protect us against infection and disease but they are also confusing. Adding Duchenne medications, pulmonary, and cardiac function to the picture adds even more confusion. In order to answer the regularly asked questions, “to give or not to give, when to give, how to give and what to give,” we have teamed up with the CDMD at UCLA to provide recommendations.
January 23, 2014 | Learn more 

News Update

BMS & The Voice of the Patient

It is a good day when a global biopharmaceutical company commits to focusing on Duchenne. We are grateful that Bristol-Myers Squibb (BMS) has added another possibility for our toolbox of hope!
January 22, 2014 | Learn more 

News Update - eNews

End Duchenne eNews: New Year, Same Mission

Catch up on the latest research and community updates in this month's End Duchenne eNews!
January 15, 2014 | Learn more 


Meet Our 2015 PPMD Adult Advisory Council

The PPMD Adult Advisory Council (PAAC) serves to ensure that the voices of adults living with Duchenne and Becker muscular dystrophy are reflected in PPMD’s legislative, policy, and program activities. PAAC members serve in a formal advisory capacity for their respective term and maintain leadership over a PAAC initiative throughout that term; PAAC initiatives are determined by the PAAC membership and PPMD Executive Team.
January 15, 2015 | Learn more 


PPMD Welcomes New CEO, John Porter, PhD

PPMD is thrilled to welcome our new CEO, Dr. John Porter! As CEO, John will help PPMD continue to integrate programs to maximize impact, building upon current programs and exploring opportunities to expand the research pipeline, with the goal of accelerating progress and approvals. John joins PPMD Founding President Pat Furlong and Chief Operating Officer, Kimberly Galberaith, in leading the organization. As founding president, Pat will continue to provide strategic direction of PPMD in support of the mission she helped set forth 20 years ago in honor of her sons and all families affected by Duchenne.
January 12, 2015 | Learn more 

News Update - Care

Update on the 2015 Flu

Even after receiving vaccination, many people are still contracting the flu this season. Read an update on the latest flu strains as well as important information on how to treat the flu if you or your child has Duchenne.
January 9, 2015 | Learn more 


Thank You! Strength Happens Together!

In early December, we asked you to help PPMD raise $400,000 for combination therapies an innovative approach to treating Duchenne. It was an ambitious goal for an ambitious project. And, thanks to YOU, we did it! In fact, we surpassed it, raising more than $430,000. Thank you to everyone who donated, thank you to Cure Dale’s Duchenne, and thank you to Rally for Ryan. Strength happens together. And together, we will end Duchenne.
January 6, 2015 | Learn more 

News Update

Heart Failure Drugs Slow Deadly Damage in Duchenne, Offering New Hope

In a new study led by Dr. Subha Raman of The Ohio State University Wexner Medical Center, researchers were able to dramatically slow the rate of heart damage in patients with Duchenne muscular dystrophy by using a combination of well-established drugs. Thank you for helping PPMD fund this promising research!
December 29, 2014 | Learn more 

News Update

Now is the time for strength.

Early next year, we plan to fund a group of research projects that, together, we believe will help us take a big step forward in ending Duchenne. We need to raise $400,000 before year-end to make that funding possible. The time is now to push that progress forward in a big way.
December 18, 2014 | Learn more 

News Update

Webinar Recording: Combination Therapies

On Wednesday, December 17th, PPMD hosted a webinar to discuss combination therapies -- a group of research projects that, together, we believe will help us take a big step forward in ending Duchenne. As you know, combination therapies are the focus of PPMD’s annual holiday campaign.
December 18, 2014 | Learn more 

News Update

The Solid Suit: Combining Forces to Enhance Strength

PPMD is excited to announce a collaboration with Solid Ventures to engage SRI International in the research and development of the “Solid Suit,” a soft, wearable assistive device for people with Duchenne.
December 18, 2014 | Learn more 

Connect with PPMD
Facebook YouTube Twitter

How We Help

Our family-centered approach is at the heart of everything we do. Learn more.

Quick Links

Fund Research

More Links

Quick Links
PPMD Sites

new amazon banner